Occam Places Steve Staben as CSO at Lycia Therapeutics
Lycia Therapeutics, Inc., a leader in extracellular protein degradation has appointed Steve Staben, Ph.D., as Chief Scientific Officer. Prior to joining Lycia, Dr. Staben spent over 14 years at Genentech leading drug discovery programs in oncology and immunology as well as new modality platforms.
Steve has co-authored over 70 peer-reviewed articles and patent applications and holds his Ph.D. in organic chemistry from the University of California, Berkeley.
Recent Placements
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.